Im vergangenen Jahr erzielte Biogen Inc für sein leistungsstärkstes Segment, Spinal Muscular Atrophy-SPINRAZA, Einnahmen von 2.15B USD. Die Region United States leistete den größten Beitrag mit 3.73B USD im letzten Jahr. Im letzten Quartal berichtete Biogen Inc über Einnahmen in Höhe von 601.70M USD für den Zeitraum bis zum 2026-06-30, die aus dem leistungsstärksten Segment, Spinal Muscular Atrophy-SPINRAZA, stammten. United States trug mit 3.91B USD den höchsten Umsatz bei.

Nach Geschäftsbereich

Umsatz

Anteil

Jährlich

Jährlich

Vierteljährlich

Spinal Muscular Atrophy-SPINRAZA

MS product revenues-TYSABRI

MS product revenues-Fumarate

MS product revenues-Interferon

Biosimilar product revenues-BENEPALI

Other-FUMADERM

Biosimilar product revenues-IMRALDI

Alzheimer's collaboration revenue

Biosimilar product revenues-FLIXABI

Biosimilars product Revenues -BYOOVIZ

MS product revenues-FAMPYRA

Alzheimer's disease:ADUHELM

Product revenues, net

Revenues from anti-CD20 therapeutic programs

Other revenues

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

Spinal Muscular Atrophy-SPINRAZA

2.15B(29.52%)

1.99B(27.33%)

1.80B(24.88%)

1.79B(22.45%)

1.91B(21.53%)

2.05B(19.19%)

--(--)

MS product revenues-TYSABRI

1.67B(22.82%)

1.72B(23.58%)

1.88B(25.90%)

2.03B(25.43%)

2.06B(23.32%)

1.95B(18.20%)

--(--)

MS product revenues-Fumarate

1.43B(19.55%)

1.60B(21.93%)

1.59B(21.92%)

2.00B(25.00%)

2.36B(26.70%)

3.91B(36.53%)

--(--)

MS product revenues-Interferon

945.60M(12.96%)

968.00M(13.31%)

1.11B(15.26%)

1.31B(16.34%)

1.57B(17.70%)

1.88B(17.56%)

--(--)

Biosimilar product revenues-BENEPALI

453.20M(6.21%)

479.10M(6.59%)

438.80M(6.06%)

441.00M(5.52%)

498.30M(5.63%)

481.60M(4.50%)

--(--)

Other-FUMADERM

197.20M(2.70%)

82.50M(1.13%)

7.80M(0.11%)

8.20M(0.10%)

11.00M(0.12%)

12.20M(0.11%)

--(--)

Biosimilar product revenues-IMRALDI

190.20M(2.61%)

213.10M(2.93%)

222.10M(3.06%)

224.50M(2.81%)

233.40M(2.64%)

216.30M(2.02%)

--(--)

Alzheimer's collaboration revenue

177.70M(2.44%)

59.90M(0.82%)

--(--)

Biosimilar product revenues-FLIXABI

52.60M(0.72%)

63.20M(0.87%)

77.40M(1.07%)

81.30M(1.02%)

99.40M(1.12%)

97.90M(0.92%)

--(--)

Biosimilars product Revenues -BYOOVIZ

33.10M(0.45%)

37.70M(0.52%)

31.70M(0.44%)

4.30M(0.05%)

--(--)

MS product revenues-FAMPYRA

1.40M(0.02%)

71.70M(0.99%)

90.50M(1.25%)

96.60M(1.21%)

105.20M(1.19%)

103.10M(0.96%)

--(--)

Alzheimer's disease:ADUHELM

--(--)

4.00M(0.06%)

4.80M(0.06%)

3.00M(0.03%)

--(--)

Product revenues, net

--(--)

11.38B(79.15%)

Revenues from anti-CD20 therapeutic programs

--(--)

2.29B(15.93%)

Other revenues

--(--)

707.70M(4.92%)

Nach Region

Umsatz

Anteil

Jährlich

Jährlich

Vierteljährlich

United States

Rest of world

United states-Revenues from anti-CD20 therapeutic

Rest of World-Other revenues

Rest of World

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

United States

3.73B(37.67%)

3.30B(34.08%)

3.14B(31.94%)

3.47B(34.10%)

3.81B(34.65%)

5.90B(43.88%)

6.71B(46.67%)

Rest of world

3.57B(36.11%)

--(--)

United states-Revenues from anti-CD20 therapeutic

1.86B(18.81%)

1.75B(18.09%)

1.69B(17.18%)

1.70B(16.72%)

1.66B(15.10%)

1.98B(14.71%)

2.29B(15.94%)

Rest of World-Other revenues

732.90M(7.41%)

652.60M(6.74%)

899.30M(9.14%)

485.10M(4.77%)

476.30M(4.34%)

774.60M(5.76%)

707.70M(4.92%)

Rest of World

--(--)

3.98B(41.09%)

4.11B(41.74%)

4.52B(44.41%)

5.04B(45.91%)

4.79B(35.64%)

4.67B(32.47%)